These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 26597925)

  • 1. Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP).
    Mihaylova B; Schlackow I; Herrington W; Lozano-Kühne J; Kent S; Emberson J; Reith C; Haynes R; Cass A; Craig J; Gray A; Collins R; Landray MJ; Baigent C;
    Am J Kidney Dis; 2016 Apr; 67(4):576-84. PubMed ID: 26597925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.
    Schlackow I; Kent S; Herrington W; Emberson J; Haynes R; Reith C; Collins R; Landray MJ; Gray A; Baigent C; Mihaylova B;
    Kidney Int; 2019 Jul; 96(1):170-179. PubMed ID: 31005271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
    Baigent C; Landray MJ; Reith C; Emberson J; Wheeler DC; Tomson C; Wanner C; Krane V; Cass A; Craig J; Neal B; Jiang L; Hooi LS; Levin A; Agodoa L; Gaziano M; Kasiske B; Walker R; Massy ZA; Feldt-Rasmussen B; Krairittichai U; Ophascharoensuk V; Fellström B; Holdaas H; Tesar V; Wiecek A; Grobbee D; de Zeeuw D; Grönhagen-Riska C; Dasgupta T; Lewis D; Herrington W; Mafham M; Majoni W; Wallendszus K; Grimm R; Pedersen T; Tobert J; Armitage J; Baxter A; Bray C; Chen Y; Chen Z; Hill M; Knott C; Parish S; Simpson D; Sleight P; Young A; Collins R;
    Lancet; 2011 Jun; 377(9784):2181-92. PubMed ID: 21663949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection.
    Herrington W; Emberson J; Staplin N; Blackwell L; Fellström B; Walker R; Levin A; Hooi LS; Massy ZA; Tesar V; Reith C; Haynes R; Baigent C; Landray MJ;
    Clin J Am Soc Nephrol; 2014 May; 9(5):914-9. PubMed ID: 24626433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.
    Sharp Collaborative Group
    Am Heart J; 2010 Nov; 160(5):785-794.e10. PubMed ID: 21095263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries.
    Ara R; Pandor A; Tumur I; Paisley S; Duenas A; Williams R; Wilkinson A; Durrington P; Chilcott J
    Clin Ther; 2008 Aug; 30(8):1508-23. PubMed ID: 18803993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD.
    Lamprea-Montealegre JA; Staplin N; Herrington WG; Haynes R; Emberson J; Baigent C; de Boer IH;
    Clin J Am Soc Nephrol; 2020 Jan; 15(1):47-60. PubMed ID: 31831577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function.
    Stanifer JW; Charytan DM; White J; Lokhnygina Y; Cannon CP; Roe MT; Blazing MA
    J Am Soc Nephrol; 2017 Oct; 28(10):3034-3043. PubMed ID: 28507057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis.
    Yang H; Li N; Zhou Y; Xiao Z; Tian H; Hu M; Li S
    Drug Des Devel Ther; 2020; 14():157-165. PubMed ID: 32021100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study.
    Reckless J; Davies G; Tunceli K; Hu XH; Brudi P
    Value Health; 2010; 13(6):726-34. PubMed ID: 20561328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Simvastatin Plus Ezetimibe for Cardiovascular Prevention in Patients With a History of Acute Coronary Syndrome: Analysis of Results of the IMPROVE-IT Trial.
    Almalki ZS; Guo JJ; Alahmari A; Alotaibi N; Thaibah H
    Heart Lung Circ; 2018 Jun; 27(6):656-665. PubMed ID: 28716519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.
    Mihaylova B; Briggs A; Armitage J; Parish S; Gray A; Collins R;
    Lancet; 2005 May 21-27; 365(9473):1779-85. PubMed ID: 15910950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States.
    Davies GM; Vyas A; Baxter CA
    J Med Econ; 2017 Jul; 20(7):723-731. PubMed ID: 28426345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation.
    Ara R; Tumur I; Pandor A; Duenas A; Williams R; Wilkinson A; Paisley S; Chilcott J
    Health Technol Assess; 2008 May; 12(21):iii, xi-xiii, 1-212. PubMed ID: 18485273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Randomized Lipid Lowering With Simvastatin and Ezetimibe on Cataract Development (from the Simvastatin and Ezetimibe in Aortic Stenosis Study).
    Bang CN; Greve AM; La Cour M; Boman K; Gohlke-Bärwolf C; Ray S; Pedersen T; Rossebø A; Okin PM; Devereux RB; Wachtell K
    Am J Cardiol; 2015 Dec; 116(12):1840-4. PubMed ID: 26602073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD.
    Morton RL; Schlackow I; Staplin N; Gray A; Cass A; Haynes R; Emberson J; Herrington W; Landray MJ; Baigent C; Mihaylova B;
    Am J Kidney Dis; 2016 Jan; 67(1):31-9. PubMed ID: 26385817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
    Cannon CP; Blazing MA; Giugliano RP; McCagg A; White JA; Theroux P; Darius H; Lewis BS; Ophuis TO; Jukema JW; De Ferrari GM; Ruzyllo W; De Lucca P; Im K; Bohula EA; Reist C; Wiviott SD; Tershakovec AM; Musliner TA; Braunwald E; Califf RM;
    N Engl J Med; 2015 Jun; 372(25):2387-97. PubMed ID: 26039521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of lowering LDL cholesterol on progression of kidney disease.
    Haynes R; Lewis D; Emberson J; Reith C; Agodoa L; Cass A; Craig JC; de Zeeuw D; Feldt-Rasmussen B; Fellström B; Levin A; Wheeler DC; Walker R; Herrington WG; Baigent C; Landray MJ; ;
    J Am Soc Nephrol; 2014 Aug; 25(8):1825-33. PubMed ID: 24790178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [LDL cholesterol lowering therapy: no target value but personalised treatment].
    Simoons ML; Deckers JW
    Ned Tijdschr Geneeskd; 2015; 159():A8770. PubMed ID: 25923500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.